In clinical practice, most dosing schemes for pharmacological treatment of epilepsy are based on efficacy (i.e. seizure reduction) and tolerability (i.e. side-effects). However, one can anticipate clinical effects (efficacy and tolerability) by measuring anti-epileptic drug (AED) serum drug concentrations (SDCs). This constellation is true for some older AEDs, such as phenytoin, since they imply regular monitoring of SDCs due to their non-linear pharmacokinetics and/or small therapeutic range [1].
16
SEP
SEP
0